These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1227 related items for PubMed ID: 20571215

  • 1. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
    Amadoro G, Corsetti V, Stringaro A, Colone M, D'Aguanno S, Meli G, Ciotti M, Sancesario G, Cattaneo A, Bussani R, Mercanti D, Calissano P.
    J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
    [Abstract] [Full Text] [Related]

  • 2. Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration.
    Amadoro G, Corsetti V, Atlante A, Florenzano F, Capsoni S, Bussani R, Mercanti D, Calissano P.
    Neurobiol Aging; 2012 Apr; 33(4):833.e1-25. PubMed ID: 21958963
    [Abstract] [Full Text] [Related]

  • 3. [Significance of tau in the development of Alzheimer's disease].
    Takashima A.
    Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
    [Abstract] [Full Text] [Related]

  • 4. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T, Maekawa S, Kimura T, Takashima A, Tomiyama T, Mori H.
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I, Barrachina M, Puig B.
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
    Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JA.
    Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897
    [Abstract] [Full Text] [Related]

  • 11. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S.
    Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Isoaspartate formation and neurodegeneration in Alzheimer's disease.
    Shimizu T, Watanabe A, Ogawara M, Mori H, Shirasawa T.
    Arch Biochem Biophys; 2000 Sep 15; 381(2):225-34. PubMed ID: 11032409
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J, Levy M, Dickson DW, Potter H.
    Brain; 2006 Nov 15; 129(Pt 11):3020-34. PubMed ID: 16987932
    [Abstract] [Full Text] [Related]

  • 18. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
    Marcus JN, Schachter J.
    J Neurogenet; 2011 Dec 15; 25(4):127-33. PubMed ID: 22091726
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The expression of calcium/calmodulin-dependent protein kinase II-alpha in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology.
    Wang YJ, Chen GH, Hu XY, Lu YP, Zhou JN, Liu RY.
    Brain Res; 2005 Jan 07; 1031(1):101-8. PubMed ID: 15621017
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 62.